Investigational New Drugs

, Volume 27, Issue 1, pp 89–98 | Cite as

Inhibition of protein synthesis by imexon reduces HIF-1α expression in normoxic and hypoxic pancreatic cancer cells

  • Betty K. Samulitis
  • Terry H. Landowski
  • Robert T. Dorr


Hypoxia-inducing factor-1 alpha (HIF-1α), is a major survival factor for tumor cells growing in a low oxygen environment. The anti-cancer agent imexon binds thiols and causes accumulation of reactive oxygen species (ROS) in pancreatic cancer cells. Unlike many cytotoxic agents, imexon is equi-cytotoxic in human MiaPaCa-2 and Panc-1 cells grown in normoxic (21% O2) and hypoxic (1% O2) conditions. Western blot analyses of imexon-treated cells demonstrated that imexon reduces HIF-1α protein levels in both normoxic and hypoxic conditions in a time- and concentration-dependant fashion. Gemcitabine did not similarly affect HIF-1α levels. Imexon did not reduce transcription of new HIF-1α mRNA, but did reduce the synthesis of new proteins, including HIF-1α, measured by 35S methionine/cysteine (Met/Cys) incorporation. Concurrently, the half-life of existing HIF-1α protein was increased by imexon, in association with a marked inhibition of chymotryptic activity in the 20S proteasome. The inhibition of HIF-1α translation was not specific, rather it was part of a general decrease in protein translation caused by imexon. This inhibitory effect on translation did not involve phosphorylation of eukaryotic initiation factor-2α (eIF-2α) and was not closely correlated to cell growth inhibition by imexon, suggesting that mechanisms other than protein synthesis inhibition contribute to the drug’s cytotoxic effects. In summary, imexon blocks the translation of new proteins, including HIF-1α, and this effect overcomes an increase in the stability of preformed HIF-1α due to proteasome inhibition by imexon. Because net HIF-1α levels are reduced by imexon, combination studies with other drugs affected by HIF-1α survival signaling are warranted.


Hypoxia Imexon Normoxia Pancreas Protein synthesis 



These studies were supported by grants CA17094 (RTD) and CA115626 (RTD) from the National Institutes of Health, Bethesda, MD.


  1. 1.
    Dragovich T, Gordon M, Mendeslon D et al (2007) Phase I trial of imexon in patients with advanced malignancy. J Clin Oncol 25:1779–1784PubMedCrossRefGoogle Scholar
  2. 2.
    Cohen SJ, Zalupski M, Modiano M, Conkling P, Patt Y, Davis P, Dorr R, Boytim M, Hersh E (2008) A phase I study of Amplimexon (AMP, imexon inj.) plus gemcitabine (Gem) as first line therapy in advanced pancreatic cancer (PC) with preclinical mechanistic study of dose limiting toxicity (DLT). Proceedings of the ASCO Annual MeetingGoogle Scholar
  3. 3.
    Iyengar BS, Dorr RT, Remers WA (2004) Chemical basis for the biological activity of imexon and related cyanoaziridines. J Med Chem 47:218–223PubMedCrossRefGoogle Scholar
  4. 4.
    Dvorakova K, Payne CM, Tome ME, Briehl MM, McClure T, Dorr RT (2000) Induction of oxidative stress and apoptosis in myeloma cells by the aziridine-containing agent imexon. Biochem Pharmacol 60:749–758PubMedCrossRefGoogle Scholar
  5. 5.
    Dvorakova K, Waltmire CN, Payne CM, Tome ME, Briehl MM, Dorr RT (2001) Induction of mitochondrial changes in myeloma cells by imexon. Blood 97:3544–3551PubMedCrossRefGoogle Scholar
  6. 6.
    Dvorakova K, Payne CM, Landowski TH, Tome ME, Halperin DS, Dorr RT (2002) Imexon activates an intrinsic apoptosis pathway in RPMI8226 myeloma cells. Anticancer Drugs 13:1–13CrossRefGoogle Scholar
  7. 7.
    Dorr RT, Raymond MA, Landowski TH, Roman NO, Fukushima S (2005) Induction of apoptosis and cell cycle arrest by imexon in human pancreatic cancer cells lines. Int J Gastrointest Cancer 36(1):15–28PubMedCrossRefGoogle Scholar
  8. 8.
    Hersh EM, Gschwind CR, Taylor CW, Dorr RT, Taetle R, Salmon SE (1992) Antiproliferative and antitumor activity of the 2-cyanoaziridine compound imexon on tumor cell lines and fresh tumor cells in vitro. J Natl Cancer Inst 84:1238–1244PubMedCrossRefGoogle Scholar
  9. 9.
    Wek RC, Jiang HY, Anthony TG (2006) Coping with stress: eIF2 kinases and translational control. Biochem Soc Trans 34(Pt 1):7–11PubMedGoogle Scholar
  10. 10.
    Tan S, Somia N, Maher P, Schubert D (2001) Regulation of antioxidant metabolism by translation initiation factor 2 alpha. J Cell Biol 152:997–1006PubMedCrossRefGoogle Scholar
  11. 11.
    Jiang HY, Wek RC (2005) Phosphorylation of the alpha-subunit of the eukaryotic initiation factor-2 (eIF2alpha) reduces protein synthesis and enhances apoptosis in response to proteasome inhibition. J Biol Chem 280(14):14189–14202PubMedCrossRefGoogle Scholar
  12. 12.
    Oettle H, Arnold D, Hempel C, Riess H (2000) The role of gemcitabine alone and in combination in the treatment of pancreatic cancer. Anticancer Drugs 11:771–786PubMedCrossRefGoogle Scholar
  13. 13.
    Poplin E, Levy DE, Berlin M (2006) Phase III trial of gemcitabine (30-minute infusion) versus gemcitabine (fixed-dose-rate infusion (FDR) versus gemcitabine + oxaliplatin (GEMOX) in patients with advanced pancreatic cancer (E6201). ASCO Proceedings 24(18s):180sGoogle Scholar
  14. 14.
    Moore MJ, Goldstein D, Hamm J et al (2007) Erlotinib plus gemcitabine compared to gemcitabine alone in patients with advanced pancreatic cancer. A phase III trial of the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG). J Clin Oncol 25(15):1960–1966PubMedCrossRefGoogle Scholar
  15. 15.
    Senderowicz AM, Johnson JR, Sridhara R, Zimmerman P, Justice R, Pazdur R (2007) Erlotinib/gemcitabine for first-line treatment of locally advanced or metastatic adenocarcinoma of the pancreas. Oncology 21:1696–1706PubMedGoogle Scholar
  16. 16.
    Koong AC, Mehta VK, Le QT et al (2000) Pancreatic tumors show high levels of hypoxia. Int J Radiat Oncol Biol Phys 48:919–922PubMedCrossRefGoogle Scholar
  17. 17.
    Megibow AJ (1992) Pancreatic adenocarcinoma: designing the examination to evaluate the clinical questions. Radiology 183:297–303PubMedGoogle Scholar
  18. 18.
    Duffy JP, Eibl G, Reber HA, Hines OJ (2003) Influence of hypoxia and neoangiogenesis on the growth of pancreatic cancer. Mol Cancer 2:12PubMedCrossRefGoogle Scholar
  19. 19.
    Kitada T, Seki S, Sakaguchi H, Sawada T, Hirakawa K, Wakasa K (2003) Clinicopathological significance of hypoxia-inducible factor-1a expression in human pancreatic carcinoma. Histopathology 43:550–555PubMedCrossRefGoogle Scholar
  20. 20.
    Buchler P, Reber HA, Buchler M et al (2003) Hypoxia-inducible factor 1 regulates vascular endothelial growth factor expression in human pancreatic cancer. Pancreas 26:56–64PubMedCrossRefGoogle Scholar
  21. 21.
    Akakura N, Kobayashi M, Horiuchi I et al (2001) Constitutive expression of hypoxia-inducible factor-1a renders pancreatic cancer cells resistant to apoptosis induced by hypoxia and nutrient deprivation. Cancer Res 61:6548–6554PubMedGoogle Scholar
  22. 22.
    Welsh SJ, Koh MY, Powis G (2006) The hypoxic inducible stress response as a target for cancer drug discovery. Semin Oncol 33:486–497PubMedCrossRefGoogle Scholar
  23. 23.
    Semenza GL, Roth PH, Fang HM, Wang GL (1994) Transcriptional regulation of genes encoding glycolytic enzymes by hypoxia-inducible factor 1. J Biol Chem 269:23757–23763PubMedGoogle Scholar
  24. 24.
    Brown JM (2002) Tumor microenvironment and the response to anticancer therapy. Cancer Biol Ther 1:453–458PubMedGoogle Scholar
  25. 25.
    Liao D, Corle C, Seagroves TN, Johnson RS (2007) Hypoxia-inducible factor-1alpha is a key regulator of metastasis in a transgenic model of cancer initiation and progression. Cancer Res 67:563–572PubMedCrossRefGoogle Scholar
  26. 26.
    Teicher BA (1994) Hypoxia and drug resistance. Cancer Metastasis Rev 13:139–168PubMedCrossRefGoogle Scholar
  27. 27.
    Yokoi K, Fidler IJ (2004) Hypoxia increases resistance of human pancreatic cancer cells to apoptosis induced by gemcitabine. Clin Cancer Res 10:2299–2306PubMedCrossRefGoogle Scholar
  28. 28.
    Sanjuan-Pla A, Cervera AM, Apostolova N et al (2005) A targeted antioxidant reveals the importance of mitochondrial reactive oxygen species in the hypoxic signaling of HIF-1alpha. FEBS Lett 579:2669–2674PubMedCrossRefGoogle Scholar
  29. 29.
    Guzy RD, Hoyos B, Robin E et al (2005) Mitochondrial complex III is required for hypoxia-induced ROS production and cellular oxygen sensing. Cell Metab 1:401–408PubMedCrossRefGoogle Scholar
  30. 30.
    Chandel NS, McClintock DS, Feliciano CE et al (2000) Reactive oxygen species generated at mitochondrial complex III stabilize hypoxia-inducible factor-1a during hypoxia: a mechanism of 02 sensing. J Biol Chem 275:25130–25138PubMedCrossRefGoogle Scholar
  31. 31.
    Simon MC (2006) Mitochondrial reactive oxygen species are required for hypoxic HIF alpha stabilization. Adv Exp Med Biol 588:165–170PubMedCrossRefGoogle Scholar
  32. 32.
    Yunis A, Arimura GK, Russin DJ (1977) Human pancreatic carcinoma (MiaPaCa-2) in continuous culture: sensitivity to asparaginase. Int J Cancer 19:128–135PubMedCrossRefGoogle Scholar
  33. 33.
    Lieber M, Mazzetta J, Nelson-Rees W, Kaplan M, Todaro G (1975) Establishment of a continuous tumor-cell line (Panc-1) from a human carcinoma of the exocrine pancreas. Int J Cancer 15:741–747PubMedCrossRefGoogle Scholar
  34. 34.
    Lightcap ES, McCormack TA, Pien CS, Chau V, Adams J, Elliott PJ (2000) Proteasome inhibition measurements: clinical application. Clin Chem 46:673–683PubMedGoogle Scholar
  35. 35.
    Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65:55–63PubMedCrossRefGoogle Scholar
  36. 36.
    Shain KH, Landowski TH, Dalton WS (2002) Adhesion-mediated intracellular redistribution of c-Fas-associated death domain-like IL-1-converting enzyme-like inhibitory protein-long confers resistance to CD95-induced apoptosis in hematopoietic cancer cell lines. J Immunol 168:2544–2553PubMedGoogle Scholar
  37. 37.
    Kisselev AF, Goldberg AL (2001) Proteasome inhibitors: from research tools to drug candidates. Chem Biol 8:739–758PubMedCrossRefGoogle Scholar
  38. 38.
    Semenza GL (2003) Targeting HIF-1 for cancer therapy. Cancer 3:721–732PubMedGoogle Scholar
  39. 39.
    Powis G, Kirkpatrick L (2004) Hypoxia inducible factor-1a as a cancer drug target. Mol Cancer Ther 3:647–654PubMedGoogle Scholar
  40. 40.
    Mabjeesh NJ, Post DE, Willard MT et al (2002) Geldanamycin induces degradation of hypoxia-inducible factor 1a protein via the proteosome pathway in prostate cancer cells. Cancer Res 62:2478–2482PubMedGoogle Scholar
  41. 41.
    Chang H, Shyu KG, Lee CC et al (2003) GL331 inhibits HIF-1a expression in a lung cancer model. Biochem Biophys Res Commun 302:95–100PubMedCrossRefGoogle Scholar
  42. 42.
    Lee YM, Kim SH, Kim HS et al (2003) Inhibition of hypoxia-induced angiogenesis by FK228, a specific histone deacetylase inhibitor, via suppression of HIF-1a activity. Biochem Biophys Res Commun 300:241–246CrossRefGoogle Scholar
  43. 43.
    Oliver VK, Patton AM, Desai S, Lorang D, Libutti SK, Kohn EC (2003) Regulation of the pro-angiogenic microenvironment by carboxyamido-triazole. J Cell Physiol 197:139–148PubMedCrossRefGoogle Scholar
  44. 44.
    Rapisarda A, Uranchimerg B, Sordet O, Pommier Y, Shoemaker PH, Belillo G (2004) Topoisomerase 1-mediated inhibition of hypoxia-inducible factor 1:mechanism and therapeutic implications. Cancer Res 64:1475–1482PubMedCrossRefGoogle Scholar
  45. 45.
    Zhong H, Chiles K, Feldser D et al (2000) Modulation of hypoxia-inducible factor 1a expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res 60:1541–1545PubMedGoogle Scholar
  46. 46.
    Raijiman I, Levin B (1995) Exocrine tumors of pancreas. In: Haubrich WS, Schaffner F (eds) Bockus gastroentrology. 5th edn. Saunders, Philadelphia, pp 2984–3001Google Scholar
  47. 47.
    Ranniger K, Saldino RM (1966) Arteriographic diagnosis of pancreas lesion. Radiology 86:470–474PubMedGoogle Scholar
  48. 48.
    Yassa NA, Yang J, Stein S, Johnson M, Ralls P (1997) Gray-scale and color flow sonography of pancreatic ductal adenocarcinoma. J Clin Ultrasound 25:473–470PubMedCrossRefGoogle Scholar
  49. 49.
    Scott J, Dorr RT, Samulitis B, Landowski TH (2007) Imexon-based combination chemotherapy in A375 human melanoma and RPMI 8226 human myeloma cell lines. Cancer Chemother Pharmacol 59:749–757PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Betty K. Samulitis
    • 1
  • Terry H. Landowski
    • 1
  • Robert T. Dorr
    • 1
  1. 1.College of Medicine, Arizona Cancer CenterUniversity of ArizonaTucsonUSA

Personalised recommendations